Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Experimental RNAi02:15

Experimental RNAi

7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Nature medicine·2026
Same author

Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.

Molecular cancer therapeutics·2025
Same author

Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth.

bioRxiv : the preprint server for biology·2025
Same author

Development of an H&E on-block staining technique for collagen detection in cryo-fluorescence tomography imaging of frozen breast tissue samples.

medRxiv : the preprint server for health sciences·2025
Same journal

Proteomic analysis of sphingolipid metabolic enzymes with risk of bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) Study.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Cancer Screening Adherence in the US by Smoking and Vaping Status, 2023.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Advancing Gastric Cancer Chemoprevention: Early Signals and Ongoing Challenges.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Will they use it? Patient and provider acceptance of chatbot screening and counseling for hereditary cancer syndromes in a geographically underserved population.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial.

Cancer prevention research (Philadelphia, Pa.)·2026
Same journal

Simvastatin Treatment in Patients with Liver Cirrhosis: a Phase II Randomized Placebo Controlled Trial Shows Reduction in IL-6 Levels.

Cancer prevention research (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer.

Cassandra L Moyer1, Jamal L Hill1, Darian Coleman1

  • 1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Prevention Research (Philadelphia, Pa.)
|October 24, 2025
PubMed
Summary
This summary is machine-generated.

Nuclear retinoid X receptor (RXR) agonists show promise in preventing triple-negative breast cancers (TNBCs). Pre-clinical studies indicate RXR agonists significantly delay tumor formation in ER-negative models, offering a potential new avenue for breast cancer prevention.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 14, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) prevent ER-positive breast cancers but not ER-negative or triple-negative breast cancers (TNBCs).
  • Nuclear estrogen receptor (ER) pathways are key targets for breast cancer prevention.

Purpose of the Study:

  • To evaluate the efficacy of nuclear retinoid X receptor (RXR) agonists, IRX4204 and 9cUAB30, in preventing ER-negative and triple-negative breast cancer (TNBC) development.
  • To explore novel therapeutic strategies for TNBC prevention beyond ER-targeted therapies.

Main Methods:

  • Testing RXR agonists IRX4204 and 9cUAB30 in three ER-negative mouse models: MMTV-ErbB2, C3(1)/SV40-TAg, and Brca1-deficient.
  • Assessing tumor formation delay, incidence, and survival rates in treated versus vehicle-controlled groups.
  • Biomarker analysis including Ki-67 expression and cytotoxic T-cell infiltration.

Main Results:

  • IRX4204 significantly delayed mammary tumor formation in all three ER-negative mouse models with modest toxicities.
  • Complete prevention of mammary tumors was observed in some MMTV-ErbB2 mice treated with IRX4204.
  • IRX4204 treatment led to decreased Ki-67 expression and increased cytotoxic T-cell infiltration in delayed tumors.
  • 9cUAB30 also delayed tumor formation in Brca1-deficient mice, though to a lesser extent than IRX4204.

Conclusions:

  • RXR agonists, particularly IRX4204, demonstrate significant pre-clinical efficacy in preventing ER-negative and triple-negative breast cancer development.
  • The findings support further investigation of RXR agonists as a prophylactic strategy for TNBC.
  • Modulation of tumor cell proliferation (Ki-67) and immune response (T-cells) are potential mechanisms underlying RXR agonist efficacy.